Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1409012/000119312510055402/d10k.htm
October 2010
July 2010
June 2010
May 2010
March 2010
February 2010
January 2010
December 2009
November 2009
August 2009
Exhibit 99.1
![]() |
11755 Wilshire Blvd., 20th Floor Los Angeles, CA 90025 | |
News Release |
ABRAXIS BIOSCIENCE REPORTS 2009 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
LOS ANGELES, Calif. March 11, 2010 Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported financial results for the fourth quarter and full year ended December 31, 2009.
As of January 2, 2009, the company re-acquired the exclusive rights to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the U.S. As a result, beginning in 2009, the company no longer recognizes deferred revenue related to the previous co-promotion agreement.
Fourth Quarter 2009 Highlights
Net revenue for the fourth quarter of 2009 was $104.7 million compared with $92.2 million for the fourth quarter of 2008. ABRAXANE revenue for the quarter of 2009 was $85.9 million compared with $89.8 million for the same period in 2008, which included recognition of deferred revenue of $9.1 million related to the co-promotion agreement. Excluding the recognition of deferred revenue, total revenue from sales of ABRAXANE for the fourth quarter of 2009 grew 6.4 percent to $85.9 million from $80.7 million for the fourth quarter of 2008. Other revenue for the fourth quarter of 2009 increased to $18.8 million from $2.3 million in the comparable period last year, primarily due to increased sales of raw material products.
Gross profit for the fourth quarter of 2009 was $84.5 million, or 81 percent of net revenue, compared with $82.8 million, or 90 percent of net revenue, for the fourth quarter of 2008. The decrease in gross margin percentage primarily reflects the increase in sales of raw material products and increased sales of ABRAXANE outside the U.S.
(more)
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1409012/000119312510055402/d10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abraxis Bioscience, Inc..
Abraxis Bioscience, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2010 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Abraxis Bioscience, Inc. provided additional information to their SEC Filing as exhibits
CIK: 1409012
Form Type: 10-K Annual Report
Accession Number: 0001193125-10-055402
Submitted to the SEC: Fri Mar 12 2010 4:23:02 PM EST
Accepted by the SEC: Fri Mar 12 2010
Period: Thursday, December 31, 2009
Industry: Pharmaceutical Preparations